fark off sb and fukwit mates

fark you gecko head and sb2000, you down ramping kunts, dont back the guru, and stick this post up ya fat overgrown lazy arsses

Size of targeted markets *The global market for pig animal health is worth around $US3.5 billion per annum, with the sector targeted by the Imugene products worth about $US1.5 billion per annum. Within that market Imugene’s E. coli product, which competes directly with Chemeq’s E. coli product, targets a market worth $US450 million. *The poultry products market is worth around $US3.2 billion with Imugene targeting a $US1.2 billion market. *Imugene’s chicken productivity enhancer market is worth about $US1 billion. *Other Imugene vaccine products are worth around $US300 million. *Imugene’s flea control vaccine research is targeting a global market for flea control products worth in excess of $US1.5 billion per annum. An efficient biological vaccine has the potential to immediately gain a large share of this market from the current over the counter chemical treatments. Highly credentialled scientists Imugene’s scientific officers are highly credentialled, closely tied to CSIRO. Dr Kevin Fahey, chairman of the Scientific Advisory Board worked with SmithKline Beecham Animal Health and most recently as Executive Director – Biological Discovery for Pfizer Global R&D. The Chief Scientific Officer Mike Sheppard also spent ten years with Smith Kline Beecham and Pfizer, the world’s largest pharmaceutical company in the US, as Director of Biological Discovery. Dr Colin Hort has been recruited from Novartis Animal Health, one of the world’s Top 10 veterinary pharmaceutical companies. This market report is provided in good faith from s o u r c e s b e l i e v e d t o b e a c c u r a t e a n d r e l i a b l e .
OzEquities directors and employees d o n o t a c c e p t l i a b i l i t y for t h e r e s u l t s o f any action taken on the
bas i s o f t h e i n forma t i on p rovided o r for an y erro r s o r omi s s i ons contained t herein.
1